{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:40:29Z","timestamp":1783698029389,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"7-8","license":[{"start":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T00:00:00Z","timestamp":1606348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T00:00:00Z","timestamp":1606348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"U.S. Department of Health\n                    & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL-097088"],"award-info":[{"award-number":["R01HL-097088"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"U.S. Department of Health\n                    & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R01GM-119186"],"award-info":[{"award-number":["R01GM-119186"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000070","name":"U.S. Department of Health\n                    & Human Services | NIH | National Institute of Biomedical Imaging and\n                    Bioengineering","doi-asserted-by":"publisher","award":["R21 EB-015684"],"award-info":[{"award-number":["R21 EB-015684"]}],"id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health\n                    & Human Services | NIH | National Institute of Neurological Disorders and\n                    Stroke","doi-asserted-by":"publisher","award":["R01NS102624"],"award-info":[{"award-number":["R01NS102624"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"U.S. Department of Health\n                    & Human Services | NIH | National Institute of Diabetes and Digestive and\n                    Kidney Diseases","doi-asserted-by":"publisher","award":["K085141"],"award-info":[{"award-number":["K085141"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gatorade Trust through funds distributed by the University of Florida\n                    Foundation Fighting Blindness"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1038\/s41434-020-00206-w","type":"journal-article","created":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T12:03:06Z","timestamp":1606392186000},"page":"447-455","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Site-specific modifications to AAV8 capsid yields enhanced brain transduction in the neonatal MPS IIIB mouse"],"prefix":"10.1038","volume":"28","author":[{"given":"Janine A.","family":"Gilkes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1119-116X","authenticated-orcid":false,"given":"Benjamin L.","family":"Judkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brontie N.","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald J.","family":"Mandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanford L.","family":"Boye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon E.","family":"Boye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2148-2868","authenticated-orcid":false,"given":"Coy D.","family":"Heldermon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,26]]},"reference":[{"key":"206_CR1","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/0009-8981(82)90273-X","volume":"122","author":"P Di Natale","year":"1982","unstructured":"Di Natale P, Murino P, Pontarelli G, Salvatore D, Andria G.\n                    Sanfilippo B syndrome (MPS III B): altered residual\n                    alpha-N-acetylglucosaminidase activity in an unusual sibship. Clin Chim Acta.\n                    1982;122:135\u201343.","journal-title":"Clin Chim Acta."},{"issue":"Suppl 1","key":"206_CR2","first-page":"133","volume":"12","author":"JA Gilkes","year":"2014","unstructured":"Gilkes JA, Heldermon CD. Mucopolysaccharidosis III (Sanfilippo\n                    Syndrome)\u2014disease presentation and experimental therapies. Pediatr Endocrinol\n                    Rev. 2014;12 Suppl 1:133\u201340.","journal-title":"Pediatr Endocrinol Rev."},{"key":"206_CR3","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/mt.2008.269","volume":"17","author":"H Petrs-Silva","year":"2009","unstructured":"Petrs-Silva H, Dinculescu A, Li Q, Min SH, Chiodo V, Pang JJ, et\n                    al. High-efficiency transduction of the mouse retina by tyrosine-mutant AAV\n                    serotype vectors. Mol Ther. 2009;17:463\u201371.","journal-title":"Mol Ther."},{"key":"206_CR4","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1128\/JVI.75.4.1824-1833.2001","volume":"75","author":"AM Douar","year":"2001","unstructured":"Douar AM, Poulard K, Stockholm D, Danos O. Intracellular\n                    trafficking of adeno-associated virus vectors: routing to the late endosomal\n                    compartment and proteasome degradation. J Virol.\n                    2001;75:1824\u201333.","journal-title":"J Virol."},{"key":"206_CR5","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1172\/JCI8317","volume":"105","author":"D Duan","year":"2000","unstructured":"Duan D, Yue Y, Yan Z, Yang J, Engelhardt JF. Endosomal processing\n                    limits gene transfer to polarized airway epithelia by adeno-associated virus. J\n                    Clin Investig. 2000;105:1573\u201387.","journal-title":"J Clin Investig."},{"key":"206_CR6","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.virol.2008.08.027","volume":"381","author":"L Zhong","year":"2008","unstructured":"Zhong L, Li B, Jayandharan G, Mah CS, Govindasamy L,\n                    Agbandje-McKenna M, et al. Tyrosine-phosphorylation of AAV2 vectors and its\n                    consequences on viral intracellular trafficking and transgene expression.\n                    Virology. 2008;381:194\u2013202.","journal-title":"Virology."},{"key":"206_CR7","doi-asserted-by":"publisher","first-page":"8968","DOI":"10.1128\/JVI.75.19.8968-8976.2001","volume":"75","author":"K Qing","year":"2001","unstructured":"Qing K, Hansen J, Weigel-Kelley KA, Tan M, Zhou S, Srivastava A.\n                    Adeno-associated virus type 2-mediated gene transfer: role of cellular FKBP52\n                    protein in transgene expression. J Virol. 2001;75:8968\u201376.","journal-title":"J Virol."},{"key":"206_CR8","doi-asserted-by":"publisher","first-page":"7827","DOI":"10.1073\/pnas.0802866105","volume":"105","author":"L Zhong","year":"2008","unstructured":"Zhong L, Li B, Mah CS, Govindasamy L, Agbandje-McKenna M, Cooper M,\n                    et al. Next generation of adeno-associated virus 2 vectors: point mutations in\n                    tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad\n                    Sci USA. 2008;105:7827\u201332.","journal-title":"Proc Natl Acad Sci USA."},{"key":"206_CR9","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1089\/hum.2010.005","volume":"21","author":"M Li","year":"2010","unstructured":"Li M, Jayandharan GR, Li B, Ling C, Ma W, Srivastava A, et al.\n                    High-efficiency transduction of fibroblasts and mesenchymal stem cells by\n                    tyrosine-mutant AAV2 vectors for their potential use in cellular therapy. Hum\n                    Gene Ther. 2010;21:1527\u201343.","journal-title":"Hum Gene Ther."},{"key":"206_CR10","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1038\/mt.2010.172","volume":"18","author":"DM Markusic","year":"2010","unstructured":"Markusic DM, Herzog RW, Aslanidi GV, Hoffman BE, Li B, Li M, et al.\n                    High-efficiency transduction and correction of murine hemophilia B using AAV2\n                    vectors devoid of multiple surface-exposed tyrosines. Mol Ther.\n                    2010;18:2048\u201356.","journal-title":"Mol Ther."},{"key":"206_CR11","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1159\/000363033","volume":"34","author":"SV Martini","year":"2014","unstructured":"Martini SV, da Silva AL, Ferreira D, Gomes K, Ornellas FM,\n                    Lopes-Pacheco M, et al. Single tyrosine mutation in AAV8 vector capsid enhances\n                    gene lung delivery and does not alter lung morphofunction in mice. Cell Physiol\n                    Biochem. 2014;34:681\u201390.","journal-title":"Cell Physiol Biochem."},{"key":"206_CR12","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/hum.2010.003","volume":"21","author":"C Qiao","year":"2010","unstructured":"Qiao C, Zhang W, Yuan Z, Shin JH, Li J, Jayandharan GR, et al.\n                    Adeno-associated virus serotype 6 capsid tyrosine-to-phenylalanine mutations\n                    improve gene transfer to skeletal muscle. Hum Gene Ther.\n                    2010;21:1343\u20138.","journal-title":"Hum Gene Ther."},{"key":"206_CR13","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/gt.2015.111","volume":"23","author":"JA Gilkes","year":"2015","unstructured":"Gilkes JA, Bloom MD, Heldermon CD. Mucopolysaccharidosis IIIB\n                    confers enhanced neonatal intracranial transduction by AAV8 but not by 5, 9 or\n                    rh10. Gene Ther. 2015;23:263\u201371. https:\/\/doi.org\/10.1038\/gt.2015.111.","journal-title":"Gene Ther"},{"key":"206_CR14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ymgmr.2015.11.006","volume":"6","author":"JA Gilkes","year":"2016","unstructured":"Gilkes JA, Bloom MD, Heldermon CD. Preferred transduction with AAV8\n                    and AAV9 via thalamic administration in the MPS IIIB model: a comparison of four\n                    rAAV serotypes. Mol Genet Metab Rep. 2016;6:48\u201354.","journal-title":"Mol Genet Metab Rep."},{"key":"206_CR15","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/S1046-2023(02)00220-7","volume":"28","author":"S Zolotukhin","year":"2002","unstructured":"Zolotukhin S, Potter M, Zolotukhin I, Sakai Y, Loiler S, Fraites TJ\n                    Jr, et al. Production and purification of serotype 1, 2, and 5 recombinant\n                    adeno-associated viral vectors. Methods. 2002;28:158\u201367.","journal-title":"Methods."},{"key":"206_CR16","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/sj.gt.3300938","volume":"6","author":"S Zolotukhin","year":"1999","unstructured":"Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K,\n                    et al. Recombinant adeno-associated virus purification using novel methods\n                    improves infectious titer and yield. Gene Ther. 1999;6:973\u201385.","journal-title":"Gene Ther."},{"key":"206_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1089\/hgtb.2013.076","volume":"24","author":"S Gholizadeh","year":"2013","unstructured":"Gholizadeh S, Tharmalingam S, Macaldaz ME, Hampson DR. Transduction\n                    of the central nervous system after intracerebroventricular injection of\n                    adeno-associated viral vectors in neonatal and juvenile mice. Hum Gene Ther\n                    Methods. 2013;24:205\u201313.","journal-title":"Hum Gene Ther Methods."},{"key":"206_CR18","doi-asserted-by":"publisher","first-page":"9928","DOI":"10.1523\/JNEUROSCI.2185-07.2007","volume":"27","author":"CN Cearley","year":"2007","unstructured":"Cearley CN, Wolfe JH. A single injection of an adeno-associated\n                    virus vector into nuclei with divergent connections results in widespread vector\n                    distribution in the brain and global correction of a neurogenetic disease. J\n                    Neurosci. 2007;27:9928\u201340.","journal-title":"J Neurosci."},{"key":"206_CR19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/gt.2015.111","volume":"23","author":"JA Gilkes","year":"2016","unstructured":"Gilkes JA, Bloom MD, Heldermon CD. Mucopolysaccharidosis IIIB\n                    confers enhanced neonatal intracranial transduction by AAV8 but not by 5, 9 or\n                    rh10. Gene Ther. 2016;23:263\u201371.","journal-title":"Gene Ther."},{"key":"206_CR20","doi-asserted-by":"publisher","first-page":"14505","DOI":"10.1073\/pnas.96.25.14505","volume":"96","author":"HH Li","year":"1999","unstructured":"Li HH, Yu WH, Rozengurt N, Zhao HZ, Lyons KM, Anagnostaras S, et\n                    al. Mouse model of Sanfilippo syndrome type B produced by targeted disruption of\n                    the gene encoding alpha-N-acetylglucosaminidase. Proc Natl Acad Sci USA.\n                    1999;96:14505\u201310.","journal-title":"Proc Natl Acad Sci USA."},{"key":"206_CR21","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/j.1399-0004.1985.tb00217.x","volume":"27","author":"J Marsh","year":"1985","unstructured":"Marsh J, Fensom AH. 4-Methylumbelliferyl\n                    alpha-N-acetylglucosaminidase activity for diagnosis of Sanfilippo B disease.\n                    Clin Genet. 1985;27:258\u201362.","journal-title":"Clin Genet."},{"key":"206_CR22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1089\/hgtb.2012.195","volume":"24","author":"D Sen","year":"2013","unstructured":"Sen D, Gadkari RA, Sudha G, Gabriel N, Kumar YS, Selot R, et al.\n                    Targeted modifications in adeno-associated virus serotype 8 capsid improves its\n                    hepatic gene transfer efficiency in vivo. Hum Gene Ther Methods.\n                    2013;24:104\u201316.","journal-title":"Hum Gene Ther Methods."},{"key":"206_CR23","doi-asserted-by":"publisher","first-page":"7752","DOI":"10.1128\/JVI.00675-12","volume":"86","author":"C Li","year":"2012","unstructured":"Li C, Diprimio N, Bowles DE, Hirsch ML, Monahan PE, Asokan A, et\n                    al. Single amino acid modification of adeno-associated virus capsid changes\n                    transduction and humoral immune profiles. J Virol.\n                    2012;86:7752\u20139.","journal-title":"J Virol."}],"updated-by":[{"DOI":"10.1038\/s41434-023-00412-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000}}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-020-00206-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-020-00206-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-020-00206-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T02:02:45Z","timestamp":1694656965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-020-00206-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,26]]},"references-count":23,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["206"],"URL":"https:\/\/doi.org\/10.1038\/s41434-020-00206-w","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41434-023-00412-2","asserted-by":"object"}]},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,26]]},"assertion":[{"value":"2 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2023","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41434-023-00412-2","URL":"https:\/\/doi.org\/10.1038\/s41434-023-00412-2","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"CDH, RJM, and AS declare stock ownership and co-founding of Lacerta\n                    Therapeutics, which develops gene therapy for CNS diseases. AS also holds\n                    several issued US Patents on AAV vectors that have been licensed to various gene\n                    therapy companies, and is a co-founder of Nirvana Therapeutics. SEB and SLB\n                    declare stock ownership and co-founding of Atsena Therapeutics, which develops\n                    gene therapies for ocular diseases.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}